CJC-1295 vs ipamorelin

At a glance

Evidence grade

The short answer

Most people searching for this comparison are not actually choosing between two products. They are looking at a single combination vial and trying to work out what each half contributes.

The answer is that the two act on different receptors that both feed growth hormone release, and one of them also lifts the brake on that release. That is the whole rationale for pairing them, and it is the part of the marketing that is straightforwardly true.

Everything sold downstream of that rationale is a separate claim needing separate evidence. The combination has not been tested in controlled human trials against the outcomes it is marketed for. What follows describes why the pairing exists. It gives no dosing, timing or route information, and no recommendation.

Two doors into the same room

The pituitary gland releases growth hormone in response to two separate signals. Growth-hormone-releasing hormone acts on its own receptor and is the body’s main accelerator for the system. Ghrelin acts on a different receptor, and it does two jobs: it amplifies release, and it suppresses the braking signal that normally holds release down.

CJC-1295 is built to act on the first receptor. Ipamorelin acts on the second. Two inputs, one output, and one of the inputs also releases the handbrake.

That is genuine pharmacology and it explains every clinic menu that carries these two together. It does not follow from any of it that the combination changes body composition, sleep, recovery, injury healing or how aging feels. Those are the claims, and the diagram is not the evidence for them.

What each side actually contributes to the record

CJC-1295 contributes a sustained hormone response. Early human work on the long-acting version reported growth hormone and IGF-1 rising and staying up. That is a real pharmacodynamic result.

Ipamorelin contributes selectivity. The compounds that came before it at the ghrelin receptor also nudged other pituitary hormones, notably cortisol and prolactin. Ipamorelin’s original pharmacology described it as releasing growth hormone with markedly less of that spillover. That is the compound’s actual scientific contribution, and it is a real reported finding rather than a marketing invention.

Both contributions are measurements of hormones in blood. Neither is a measurement of a person doing better.

The asymmetry the vial label hides

These two compounds are not equally identifiable. Ipamorelin means one molecule. CJC-1295 does not.

CJC-1295 was developed with a drug affinity complex, usually shortened to DAC, which lets it bind albumin in the blood and resist quick clearance. That long-acting form is the one taken into early human trials. A great deal of what is sold under the CJC-1295 name is labeled "without DAC" or "no DAC", and that is a different molecule: modified GRF(1-29), a short-acting analogue with its own profile.

So the two halves of a combination vial do not carry equally interpretable evidence. Whatever the ipamorelin literature says applies to the ipamorelin in the vial. Whether the CJC-1295 literature applies depends on which version is in there, and vendors are not reliably clear about it.

A rationale is not a result

Combining a growth-hormone-releasing hormone analogue with a ghrelin receptor agonist has a coherent basis. It is easy to see why someone built the pairing.

It has not been studied as a combination in controlled human trials measuring the outcomes it is sold for. There is a difference between a combination that makes sense and a combination that has been tested, and this market routinely treats the first as though it settled the second.

Be precise about what the best available evidence measures even at its strongest. Growth hormone went up. IGF-1 went up. That is not a demonstration that fat mass, lean mass, sleep quality, recovery time, joint pain or subjective wellbeing changed — and those are the things people are actually paying for.

Where the regulatory question sits

Neither CJC-1295 nor ipamorelin is an FDA-approved drug in the United States. Neither sits in a settled compounding position, and nothing about either one is currently pending. No outcome, timeline or likelihood is stated here.

Each compound has its own dated status record on this site, and that record is where the current position is stated. A summary written into a comparison page drifts out of date the moment the record changes, so none appears here.

One point stands regardless of how any of that resolves. Material sold in vials labeled for research use only sits outside the prescription drug supply chain, and it carries no assurance of identity, purity, sterility or content. That is a different category of thing from a compounded prescription prepared by a licensed pharmacy for a named patient. Both circulate under these two compound names.

How the grades were set

Both are graded limited evidence. Each has a defined receptor and a documented human effect on growth hormone release, which places them above compounds whose case rests entirely on cell culture and animal models. Neither has controlled outcome data for the uses it is sold for, which keeps both well short of strong.

The qualification is on the CJC-1295 side. Its grade is carried by the studied version, the long-acting DAC form. A buyer holding a vial labeled "no DAC" is holding something with less behind it than the grade implies.

A grade here is not a ranking of the two compounds against each other. Both would move only on the same kind of evidence: randomized, placebo-controlled trials in the adults being sold the product, measuring outcomes those adults would notice.